• President Biden proclaims February as American Heart Month
• Annual tradition provides opportunity to focus on nationwide problem of heart and blood-vessel diseases
• HeartBeam is committed to being part of the solution for identifying, treating heart attacks

Following a decades-long tradition, President Joseph Biden issued a proclamation from the White House declaring February as American Heart Month (https://ibn.fm/6Z9Iq). This nationwide focus on heart health is fully supported by HeartBeam (NASDAQ: BEAT), a cardiac technology company dedicated to leading the way in finding effective ways to detect heart attacks earlier than ever before.

“During American Heart Month, we recommit to supporting the more than 120 million Americans living with a cardiovascular condition; advancing groundbreaking and lifesaving research; and expanding access to affordable health care, prescription drugs, and healthy lifestyles,” the White House proclamation stated. “Heart disease has long been the leading cause of death in the United States, claiming nearly 700,000 lives a year.

“Nearly half of all American adults have at least one major risk factor for cardiovascular disease,” the statement continued. “From heart attacks and strokes to high blood pressure, the threat of cardiovascular disease touches almost every family in our nation. But while heart conditions can be costly and deadly, they are also often preventable with access to affordable health care, advancements in technology and lifestyle changes.”

American Heart Month is a longstanding tradition. President Lyndon B. Johnson established the tradition when he issued Presidential Proclamation 3566 in December 1963, 10 days after Congress issued a joint resolution requesting the president to issue an annual proclamation (https://ibn.fm/v2Sv2). In announcing February 1964 as the first American Heart Month, President Johnson urged “the people of the United States to give heed to the nationwide problem of the heart and blood-vessel diseases, and to support the programs required to bring about its solution.”

HeartBeam is committed to being part of the solution for identifying and treating heart attacks.

The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection.

Noting that every 40 seconds someone in the United States has a heart attack, or myocardial infarction (“MI”), HeartBeam points out that many people second-guess their heart-attack symptoms (https://ibn.fm/FmgJa). “Unfortunately, there is no way for patients to tell if the symptoms they are experiencing are due to an MI. As a result, patients often ignore symptoms and delay seeking care, which leads to worse outcomes and increased mortality.” 

HeartBeam is developing a personal, portable and easy-to-use heart-attack detection solution. People will be able to use the system anytime, anywhere to help their clinicians determine if chest pain is the result of a heart attack, leading to faster identification and treatment. “For the first time outside of a medical setting, physicians can determine with a patient-friendly device if chest pains are due to a heart attack,” the company reports.

Although HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”), the company is “on track with our HeartBeam AIMIGo 3D vector ECG first-generation product, which we expect will be ready for FDA submission in Q1 2023, and the anticipated FDA clearance for our HeartBeam AIMI system,” wrote HeartBeam founder and CEO Branislav Vajdic, PhD, in a recent shareholder report (https://ibn.fm/zRZA7).

“We are leveraging our strategic partnerships with multiple industry leaders to move toward production and commercialization of our products, with plans to broaden our product portfolio pipeline with smartwatch connectivity,” Vajdic continued. “Our commercial team has continued to engage in productive discussions with strategic healthcare institutions, including academic centers, regional systems, and regional community hospital systems. We enter 2023 with tremendous momentum and look forward to sharing our accomplishments in the coming year as we strive to create value for our customers, shareholders, employees, and communities.”

For more information, visit the company’s website at www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all